Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech, Inc. director and President, R&D Suma Krishnan reported open-market sales of 25,000 shares of common stock. The transactions took place on June 4, 2026 in multiple trades at prices generally ranging from about $300.75 to $311.65 per share.
The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to run until December 4, 2026 unless completed earlier. Krishnan also reports indirect ownership of 50,000 shares through the Krishnan Family Trust and 90,000 shares through the Krishnan Spousal Trust.
Krystal Biotech, Inc.’s President and CEO Krish S. Krishnan reported open-market sales of 25,000 shares of common stock on June 4, 2026. The shares were sold in multiple trades with reported weighted average prices such as $312.23 and $300.75 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these transactions, Krishnan directly holds 1,474,933 shares and indirectly holds 90,000 shares through the SMK Trust FBO KSK and 50,000 shares through the Krishnan Family Trust, where he shares voting and investment power. Shares directly owned by his spouse are reported separately and are disclaimed except for any pecuniary interest.
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles sold 642 shares of common stock in an open-market transaction. The shares were sold at an average price of $302.03 per share on May 26, 2026, and his directly held common stock position reported in this filing is now zero shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which is scheduled to run through December 31, 2026 unless it terminates earlier under its terms.
Krystal Biotech, Inc. reported results of its 2026 annual stockholder meeting held on May 15, 2026. Stockholders elected Class III directors Krish S. Krishnan and Christopher Mason for three-year terms, each receiving over 22 million votes in favor with additional broker non-votes recorded.
Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with over 28.4 million votes for and minimal opposition. In a non-binding advisory vote, stockholders approved named executive officer compensation for 2025, and unaffiliated stockholders approved the company’s Non-Employee Director Compensation Policy after excluding directors and certain litigation defendants from voting on that item.
Krystal Biotech insiders Krish S. Krishnan and Suma M. Krishnan jointly filed Amendment No. 3 to their Schedule 13G/A reporting an aggregate 3,388,283 shares of Common Stock, representing 11.5% of the class. The percentage is based on 29,479,756 shares outstanding as of April 29, 2026. The filing breaks down holdings as directly owned shares, shares held in family and spousal trusts, and stock options exercisable for 158,525 and 121,350 shares respectively. The Reporting Persons state shared voting and dispositive power over the aggregate amount and include a Joint Filing Agreement as Exhibit 99.1.
Krystal Biotech reported strong first quarter 2026 results, driven by VYJUVEK gene therapy sales and advancing its genetic medicine pipeline. VYJUVEK net product revenue reached $116.4 million in Q1 2026, a 32% increase over the prior-year quarter, with a gross margin of 95%.
Net income rose to $55.9 million, or $1.83 per diluted share, compared with $35.7 million, or $1.20 per diluted share, in Q1 2025. The company ended the quarter with a $1.0 billion cash and investment balance, supporting ongoing commercial and R&D activities.
Management highlighted global VYJUVEK uptake, including over 695 U.S. reimbursement approvals and growing European use, alongside multiple late-stage programs. Two ophthalmology registrational readouts are anticipated in 2026, and the FDA granted platform technology designation for KB407 and KB111, reinforcing the company’s HSV-1-based gene therapy platform.
Krystal Biotech, Inc. reported strong profitability for the quarter ended March 31, 2026, driven by rapid uptake of its gene therapy VYJUVEK. Product revenue, net rose to $116.4 million from $88.2 million a year earlier, largely from growth in Europe and Japan.
Gross margin was 95%, while net income increased to $55.9 million from $35.7 million. Diluted net income per share was $1.83, up from $1.20. Cash, cash equivalents and short-term investments totaled about $823.4 million, and the company reported retained earnings of $80.1 million, highlighting a solid balance sheet to fund its expanding clinical pipeline across ophthalmology, respiratory, dermatology, oncology and aesthetics.